NCT01248000

The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 136 (actual)
• Sponsor: Gruppo Italiano Studio Linfomi · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.

Conditions

• Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

Interventions

Type	Name	Description
PROCEDURE	FDG-PET	PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)

Timeline

• Start date: 2009-05-01
• Completion: 2010-05-01
• First posted: 2010-11-25
• Last updated: 2010-11-25

Locations

1 site across 1 country: Italy